David Doherty Sells 14,574 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CFO David Doherty sold 14,574 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $13.84, for a total transaction of $201,704.16. Following the completion of the sale, the chief financial officer owned 88,803 shares in the company, valued at $1,229,033.52. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Surgery Partners Stock Performance

NASDAQ SGRY traded down $0.06 on Monday, reaching $13.30. 1,453,571 shares of the company’s stock traded hands, compared to its average volume of 1,733,344. Surgery Partners, Inc. has a fifty-two week low of $12.25 and a fifty-two week high of $24.60. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -21.45 and a beta of 1.95. The stock has a 50 day moving average price of $15.16 and a 200-day moving average price of $18.00.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). The company had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.44 EPS. Equities research analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners declared that its Board of Directors has initiated a share buyback plan on Thursday, February 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to purchase up to 9.7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Mizuho decreased their price objective on shares of Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. TD Cowen reduced their price target on Surgery Partners from $28.00 to $20.00 and set a “buy” rating for the company in a report on Thursday. Finally, UBS Group dropped their price objective on Surgery Partners from $29.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Surgery Partners currently has an average rating of “Moderate Buy” and a consensus price target of $24.45.

Key Headlines Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Hedge Funds Weigh In On Surgery Partners

Hedge funds have recently made changes to their positions in the company. Jones Financial Companies Lllp increased its position in shares of Surgery Partners by 313.1% during the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after purchasing an additional 930 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Surgery Partners by 45,640.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock valued at $49,000 after purchasing an additional 2,282 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Surgery Partners by 128.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock worth $58,000 after purchasing an additional 1,519 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Surgery Partners during the third quarter worth $121,000. Finally, State of Alaska Department of Revenue purchased a new stake in shares of Surgery Partners during the third quarter worth $151,000.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.